3 results match your criteria: "From the Beth Israel Deaconess Medical Center-Harvard Medical School[Affiliation]"
Postoperative Ataxic Breathing: A New Tool for Early Diagnosis of Opioid-Induced Respiratory Depression?
Anesth Analg
December 2024
From the Beth Israel Deaconess Medical Center-Harvard Medical School, Boston, Massachusetts.
Factors Associated With Surgical Site Infections After Fasciotomy in Patients With Compartment Syndrome.
J Am Acad Orthop Surg Glob Res Rev
February 2022
From the Beth Israel Deaconess Medical Center-Harvard Medical School (Dr. Merchan, Ingalls, and Garcia); the Department of Orthopaedic Trauma, Beth Israel Deaconess Medical Center-Harvard Medical School (Dr. Wixted); the Department of Hand and Upper Extremity Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School (Dr. Rozental, and Dr. Harper); and the Department of Hand and Upper Extremity Surgery, Harvard Medical School (Dr. Dowlatshahi), Boston, MA.
Introduction: Fasciotomy is the standard of care to treat acute compartment syndrome (ACS). Although fasciotomies often prevent serious complications, postoperative complications can be notable. Surgical site infection (SSI) in these patients is as high as 30%.
View Article and Find Full Text PDFInternational Consensus Guidance for Management of Myasthenia Gravis: 2020 Update.
Neurology
January 2021
From the Beth Israel Deaconess Medical Center/Harvard Medical School (P.N.), Boston, MA; Department of Neurology (D.B.S., J.M.), Duke University Medical Center, Durham, NC; Department of Neurology (G.W.), Univ. at Buffalo Jacobs School of Medicine and Biomedical Sciences, State University of New York, Buffalo, NY; Department of Neurology (M.B.), University of Miami, Miller School of Medicine. Miami, FL; Gabriel Cea (G.C.), Departamento de Ciencias Neurologicas, Facultad de Medicina, Universidad de Chile, Santiago, Chile; Dipartimento di Neuroscienze (A.E.), Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy; Department of Clinical Medicine (N.E.G.), University of Bergen, Norway; Isabel Illa (I.I.), Department of Neurology, Hospital Santa Creu i Sant Pau. Universitat Autònoma de Barcelona, Barcelona, ERN EURO-NMD and CIBERER U762, Spain; Departments of Pediatrics and Neurology (N.L.K.), Northwestern Feinberg School of Medicine, Chicago, IL; Neurology (A.M.), University of Tübingen Medical Centre, Tübingen, Germany; Department of Neurology (H.M.), International University of Health and Welfare, Narita, Japan; Department of Clinical Neurological Sciences (M.N.), Western University, London, ON, Canada; Department of Clinical Neurology (J.P.), John Radcliffe Hospital, Oxford University Hospitals Trust, Oxford, UK; Department of Neurology (D.R.), University of California, Davis, Davis, CA; and Department of Neurology (J.V.), Leiden University Medical Centre, Leiden, the Netherlands.
Objective: To update the 2016 formal consensus-based guidance for the management of myasthenia gravis (MG) based on the latest evidence in the literature.
Methods: In October 2013, the Myasthenia Gravis Foundation of America appointed a Task Force to develop treatment guidance for MG, and a panel of 15 international experts was convened. The RAND/UCLA appropriateness method was used to develop consensus recommendations pertaining to 7 treatment topics.